Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane

Endocrine-Related Cancer

Volumn 20, Issue 3, 2013, Pages 443-454

  Van Koetsveld, Peter M ^a   Vitale, Giovanni ^a,b,c   Feelders, Richard A ^a   Waaijers, Marlijn ^a   Sprij Mooij, Diana M ^a   De Krijger, Ronald R ^a   Speel, Ernst Jan M ^d   Hofland, Johannes ^a   Lamberts, Steven W J ^a   De Herder, Wouter W ^a   Hofland, Leo J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MILAN   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Adrenocortical carcinoma; Insulin like growth factor 2; Interferon receptor; Mitotane; Type 1 interferons

Indexed keywords

BETA INTERFERON; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYTOCHROME P450; CYTOCHROME P450 11B1; CYTOCHROME P450 17A1; DNA; HYDROCORTISONE; MESSENGER RNA; MITOTANE; SOMATOMEDIN B; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL COUNT; CHEMOSENSITIZATION; CONTROLLED STUDY; DNA CONTENT; HUMAN; HUMAN CELL; HYDROCORTISONE RELEASE; IN VITRO STUDY;

ADRENOCORTICAL CARCINOMA; INSULIN-LIKE GROWTH FACTOR 2; INTERFERON RECEPTOR; MITOTANE; TYPE 1 INTERFERONS;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; HYDROCORTISONE; INSULIN-LIKE GROWTH FACTOR II; INTERFERON-BETA; MALE; MIDDLE AGED; MITOTANE; PHOSPHOPROTEINS; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84879483536     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0217     Document Type: Article

References (36)

1. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X & Bertherat J 2006 Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. Journal of Clinical Endocrinology and Metabolism 91 2650-2655. (doi:10.1210/jc.2005-2730)
2. Allolio B & Fassnacht M 2006 Clinical review: adrenocortical carcinoma: clinical update. Journal of Clinical Endocrinology and Metabolism 91 2027-2037. (doi:10.1210/jc.2005-2639)
3. Almeida MQ, Fragoso MC, Lotfi CF, Santos MG, Nishi MY, Costa MH, Lerario AM, Maciel CC, Mattos GE, Jorge AA et al. 2008 Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 93 3524-3531. (doi:10.1210/jc.2008-0065)
4. Asp V, Ulleras E, Lindstrom V, Bergstrom U, Oskarsson A & Brandt I 2010 Biphasic hormonal responses to the adrenocorticolytic DDT metabolite 3-methylsulfonyl-DDE in human cells. Toxicology and Applied Pharmacology 242 281-289. (doi:10.1016/j.taap.2009.10.018)
5. Bekisz J, Baron S, Balinsky C, Morrow A & Zoon KC 2010 Antiproliferative properties of type I and type II interferon. Pharmaceuticals 3 994-1015. (doi:10.3390/ph3040994)
6. Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F et al. 2005 Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocrine-Related Cancer 12 657-666. (doi:10.1677/erc.1.01025)
7. Buchwalder PA, Buclin T, Trinchard I, Munafo A & Biollaz J 2000 Pharmacokinetics and pharmacodynamics of IFN-b1a in healthy volunteers. Journal of Interferon & Cytokine Research 20 857-866. (doi:10.1089/ 10799900050163226)
8. Chai W, Hofland J, Jansen PM, Garrelds IM, de Vries R, van den Bogaerdt AJ, Feelders RA, de Jong FH & Danser AH 2010 Steroidogenesis vs. steroid uptake in the heart: do corticosteroids mediate effects via cardiac mineralocorticoid receptors? Journal of Hypertension 28 1044-1053. (doi:10.1097/HJH.0b013e328335c381)
9. Erdmann J, Vitale G, van Koetsveld PM, Croze E, Sprij-Mooij DM, Hofland LJ & van Eijck CH 2011 Effects of interferons α/β on the proliferation of human micro- and macrovascular endothelial cells. Journal of Interferon & Cytokine Research 31 451-458. (doi:10.1089/jir. 2009.0103)
10. Fassnacht M, Libe R, Kroiss M & Allolio B 2011 Adrenocortical carcinoma: a clinician's update. Nature Reviews. Endocrinology 7 323-335. (doi:10.1038/nrendo.2010.235)
11. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin PF, Baudin E et al. 2005 Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. Journal of Clinical Endocrinology and Metabolism 90 1819-1829. (doi:10.1210/jc.2004-1075)
12. Hahner S & Fassnacht M 2005 Mitotane for adrenocortical carcinoma treatment. Current Opinion in Investigational Drugs 6 386-394.
13. Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A, Chadarevian R, Schlumberger Met al. 2011 Plasma concentrations of o, p'DDD, o, p'DDA, and o, p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. Journal of Clinical Endocrinology and Metabolism 96 1844-1851. (doi:10.1210/jc.2010-2676)
14. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW et al. 2005 The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. European Journal of Endocrinology 152 645-654. (doi:10.1530/eje.1.01876)
15. Johanssen S, Fassnacht M, Brix D, Koschker AC, Hahner S, Riedmiller H & Allolio B 2008 Adrenocortical carcinoma. Diagnostic work-up and treatment. Der Urologe 47 172-181. (doi:10.1007/s00120-007-1578-0)
16. Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ & Linnane AW 1992 Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon β. Journal of the National Cancer Institute 84 1185-1190. (doi:10.1093/jnci/84.15.1185)
17. Khan TS, Imam H, Juhlin C, Skogseid B, Grondal S, Tibblin S, Wilander E, Oberg K & Eriksson B 2000 Streptozocin and o, p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Annals of Oncology 11 1281-1287. (doi:10.1023/A:1008377915129)
18. van Koetsveld PM, Vitale G, de Herder WW, Feelders RA, van der Wansem K, Waaijers M, van Eijck CH, Speel EJ, Croze E, van der Lely AJ et al. 2006 Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. Journal of Clinical Endocrinology and Metabolism 91 4537-4543. (doi:10.1210/jc.2006-0620)
19. Lin CW, Chang YH & Pu HF 2012 Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells. Toxicology 298 14-23. (doi:10.1016/j.tox. 2012.04.007)
20. Morimoto R, Satoh F, Murakami O, Suzuki T, Abe T, Tanemoto M, Abe M, Uruno A, Ishidoya S, Arai Y, Takahashi K, Sasano H & Ito S 2008 Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas:Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocrine Journal 55 49-55. (doi:10.1057/endocrj.K07- 079)
21. Ogasawara S, Yano H, Momosaki S, Akiba J, Nishida N, Kojiro S, Moriya F, Ishizaki H, Kuratomi K & Kojiro M 2007 Growth inhibitory effects of IFN-β on human liver cancer cells in vitro and In vivo. Journal of Interferon & Cytokine Research 27 507-516. (doi:10.1089/jir.2007.0183)
22. Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyanathan S, Green M, Baker DP, Whalley E, Hochman PS & Martin P 2001 Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-β-1a with preserved in vitro bioactivity. Journal of Pharmacology and Experimental Therapeutics 297 1059-1066. (doi:10.1021/bm0701604)
23. Pfaffl MW 2001 A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Research 29 e45. (doi:10.1093/nar/29.9.e45)
24. Pushkarev VM, Tronko ND, Kostyuchenko NN & Mikosha AS 2007 Effect of o, p′-DDD and Li+ on apoptotic DNA fragmentation in conventionally normal and tumour tissues of human adrenal cortex. Ukraïns'kyí Biokhimichnyí Zhurnal 79 44-49.
25. Rasmussen R 2001 Quantification on the Light Cycler. In Rapid Cycle Real-Time PCR. Methods and Applications, pp 21-34. Eds S Meuer, G Wittwer & K Nakagawara. Heidelberg: Springer Press.
26. van't Sant HP, Bouvy ND, Kazemier G, Bonjer HJ, Hop WC, Feelders RA, de Herder WW & de Krijger RR 2007 The prognostic value of two different histopathological scoring systems for adrenocortical carcinomas. Histopathology 51 239-245. (doi:10.1111/j.1365-2559.2007. 02747.x)
27. Schmittgen TD & Livak KJ 2008 Analyzing real-time PCR data by the comparative C(T) method. Nature Protocols 3 1101-1108. (doi:10.1038/nprot.2008. 73)
28. Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M & Worden FP 2005 Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocrine-Related Cancer 12 667-680. (doi:10.1677/erc.1.01029)
29. Slater EP, Diehl SM, Langer P, Samans B, Ramaswamy A, Zielke A & Bartsch DK 2006 Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. European Journal of Endocrinology 154 587-598. (doi:10.1530/eje.1.02116)
30. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E et al. 2007 Adjuvant mitotane treatment for adrenocortical carcinoma. New England Journal of Medicine 356 2372-2380. (doi:10.1056/NEJMoa063360)
31. Uyama H, Nagano H, Nakamura H, Murakami T, Monden M & Hayashi N 2007 New chemotherapy for patients with advanced hepatocellular carcinoma: Pilot study of β-interferon and doxorubicin one-shot intra-arterial chemotherapy. Hepatology Research 37 1018-1025. (doi:10.1111/j.1872-034X.2007.00158.x)
32. Veytsman I, Nieman L & Fojo T 2009 Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. Journal of Clinical Oncology 27 4619-4629. (doi:10.1200/JCO.2008.17.2775)
33. Vitale G, van Eijck CH, van Koetsveld Ing PM, Erdmann JI, Speel EJ, van der Wansem Ing K, Mooij DM, Colao A, Lombardi G, Croze E et al. 2007 I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Annals of Surgery 246 259-268. (doi:10.1097/01.sla. 0000261460.07110.f2)
34. Vitale G, Caraglia M, van Koetsveld PM, Maroni P, Marra M, Colao A, Lamberts SW, Cavagnini F & Hofland LJ 2009 Potential role of type I interferons in the treatment of pituitary adenomas. Reviews in Endocrine and Metabolic Disorders 10 125-133. (doi:10.1007/s11154-008-9083-3)
35. Volante M, Buttigliero C, Greco E, Berruti A & Papotti M 2008 Pathological and molecular features of adrenocortical carcinoma: an update. Journal of Clinical Pathology 61 787-793. (doi:10.1136/jcp.2007.050625)
36. de Weerd NA, Samarajiwa SA & Hertzog PJ 2007 Type I interferon receptors: biochemistry and biological functions. Journal of Biological Chemistry 282 20053-20057. (doi:10.1074/jbc.R700006200)